Life Sciences Archive » December, 2009

Life Sciences - December, 2009

147 articles

• AstraZeneca Unit Pulls H1N1 Vaccines
• Breg Braces For Bledsoe Patent Suit
• Rigel Securities Suit Tossed On Specificity Grounds
• Roche's Mircera Banned From U.S. In Amgen's Win
• Genzyme Board Sued Over Drug Delays, Insider Deals
• Schering Sues Apotex Over Nasonex ANDA
• NY Court Boots Ga. Man's Lipitor Case Against Pfizer
• Ill. Drug-Flushing Law Takes Effect In New Year
• Q&A With Burns & Levinson's Josef Volman
• Class Cert. Sought In Suit Over 'Snake-Oil' CVS Item
• 3rd Circ. Vacates Class Cert. In Schering ERISA Suit
• Fosamax MDL Plaintiff Takes Case To 2nd Circ.
• Lupin Gets Namenda License In Forest Settlement
• Negligence Claims Against J&J, Subsidiary Dismissed
• Lilly To Pay Up To $755M For Autoimmune Treatments
• Sex Bias Plaintiffs Seek Sanctions Against Novartis
• Actelion To Lose $80M After Arbitration Ruling
• Abbott Hits Sandoz On Generic Nimbex In Del., NJ
• Former Biovail CFO Settles In SEC Fraud Suit
• Schering Targets Mylan Over Vytorin ANDA
• Have You Reviewed Your Royalty Agreements Lately?
• Abbott Appeals $1.9B Hit In Patent Suit Over Humira
• Cephalon Loses Round In JHU Leukemia Patent Suit
• Boehringer Tries To Derail Mirapex Antitrust Suits
• DLA Piper Ex-Partner Opens Anti-Counterfeiting Firm
• Sanofi-Aventis Snaps Up Chattem For $1.9B
• Medical Suppliers Resolve Marketing Dispute
• Senate Moves Forward With Health Care Vote
• Pfizer Puts $6M Down On Rights To Stem Cell Therapy
• Bayer Wins Ill. Class Action Over Baycol Marketing
• Dr. Reddy's Loses Zyprexa Patent Fight In UK Court
• Interest Pushes Humira Award Up To $1.85B
• 2nd Circ. Won't Force HPV Test Reclassification
• Q&A With Choate's Robert Frank Jr.
• Jury Invalidates Hologic Patents In Suit Against Rival
• Merck Singulair Patent Survives USPTO Re-Exam
• The Medicines Co. Issues Blood Pressure Drug Recall
• Pfizer Execs Seek Dismissal Of Derivative Suit
• Still In Hot Seat, FDA Opens Mexico City Outpost
• Amgen Says ERISA Anemia Drug Claims Lack Merit
• Schering Settles Medi-Cal Fraud Suit For $21M
• Ethicon To Snap Up Acclarent For $785M
• South Florida Reclaims Place As Top 'Judicial Hellhole'
• Cephalon Files 3rd Suit Over Planned Generic Nuvigil
• Hospira Adds Orchid Generic Antibiotic Unit For $400M
• FDA Warns Abbott Unit Over Eye Device Manufacturing
• Md. Insurance Boss To Join FDA As Chief Counsel
• AstraZeneca Loses Appeal In Generic Prilosec Feud
• SEC Drops Anthrax Civil Case Against Convicted Exec
• Sales Reps Hit Sanofi With Overtime Action
• Bellwether Consolidation Denied In Levaquin MDL
• Appeals Court Nixes Vioxx Plaintiffs' Class Cert. Bid
• Senators Reject Drug Importation Measure
• Pfizer, Businessman Settle Viagra Missile Suit
• Abbott To Buy Starlims In $123M Cash Deal
• Research Tools Sail Out Of The Safe Harbor
• Sanofi Recalls Weakening Swine Flu Vaccine Doses
• Blood Processing Co. Sues Rival Again Over Centrifuge
• Wellbutrin Indirect Buyers Seek Cert. In Antitrust Suit
• Inequitable Conduct Still In Play In Crestor Suit
• Judge Chucks NeuroMetrix Shareholder Action
• WellNx Diet Pill Marketing Fraud Suit Survives
• NuvaRing Judge Scolds Defense Over Slew Of Motions
• USPTO Declares Stem Cell Patent Interference
• Bayer Once More Defending Trasylol In Federal Court
• Biotech Co. Given Chance To Fix Mintz Levin Suit
• King Pharm.'s Advertising Suit Against Rival Hits Snag
• Some Counterclaims Tossed In Roche Suit Over Xeloda
• Is There A Written Description Requirement After All?
• GSK Forced To Turn Over Docs In Avandia MDL
• Q&A With Lowenstein Sandler's Douglas Eakeley
• P&G's Crest Whitestrips Targeted In Patent Suit
• Novartis, Bayer Near Deal Over Hemophilia Drugs
• SEC Kicks Off Wide Insider Trading Investigation
• Judge Rebuffs Teva Discovery Bid In Aricept IP Suit
• FDA Panel Finds Fatal Risks In GE, Covidien MRI Drugs
• FDA Questions Low-Cost Drug Import Legislation
• FDA Warns Sorin Over Inadequate Incident Reports
• FDA Should Beef Up Post-Market Drug Safety: GAO
• Bayer Recalls Alka-Seltzer Gel Caps Over Mislabeling
• EU Raids Lundbeck, Others In Antitrust Probe
• Patent Pools In The Life Sciences
• Mylan, Wyeth Reach Accord On Effexor XR
• Actavis Loses Bid To Toss Generic Reglan Claim
• CORRECTED: Diversity Of Clients Puts Skadden On Top
• Lilly, 3rd-Party Payor Class Argue Zyprexa Appeal
• Clarity In Chinese Merger Review Procedures?
• Medtronic 'Denies Reality' In Pacemaker Case: Judge
• House Panel Raises Alarms Over Drug Price Increases
• Ranbaxy Admits To Infringing Purdue OxyContin Patent
• Fed. Circ. Nixes Tyco Ultrasonic Device Patent Suit
• Cephalon Sues Teva Over Plan For Generic Nuvigil
• FDA Issues Warning On Voltaren Gel Liver Risks
• Mayer Brown 1st-Years Asked To Sit Tight Till Oct. 2010
• Combating Abusive Pleading With Iqbal/Twombly
• Celgene To Snap Up Gloucester Pharma For $640M
• Unilever Settles Potassium Supplement Suit For $1.4M
• Sens. Reject Limit On Medical Malpractice Attys' Fees
• 11th Circ. Upholds Toss Of Solvay Marketing Suit
• Conn. AG To Probe Health Net-UnitedHealth Deal
• $14M Deal Wins Final OK In Long-Running Dura Case
• Steris In Hot Water Again Over Sterilization Device
• FDA Asked To Look At Drugs' Impact On Child Weight
• Biogen Angles For Facet With 2nd Hostile Bid
• Merck KGaA Wants Brookstone's 'False Generic' Yanked
• Shook Hardy Keeps Clients Coming Back
• Teva, Mylan Clarify Copaxone Patent Claims
• IP Attorneys Dominate At Fish & Richardson
• Finnegan Stays No. 1 In Downturn
• Pharmacies' Suit Over Pfizer-Wyeth Merger Dismissed
• Financial Discipline Keeps Wilson Sonsini On Top
• Product Liability Attorneys Dominate At Bowman Brooke
• Another Darby & Darby Atty Leaves For McDermott
• Ariad V. Eli Lilly And Written Description Requirement
• Matrixx, Capricorn Resolve Zicam Contract Spat
• Pfizer Adds New Suit To Litigation Over Lipitor ANDAs
• Kohl Pitches Stricter Pay-For-Delay Drug Rules
• Sanofi-Aventis Warns Of Norpramin Heart Attack Risk
• Sonnenschein Scores Dickstein Corporate Partner
• GSK Warns Of HIV Drug's Heart Attack Risk
• Roche Wins Transfer Of Novartis' Patent Case To NC
• Consumer Group Seeks Ban Of Abbott's Meridia Drug
• McDermott Snags Biotech Atty From Fish & Richardson
• Takeda Sues Watson Over Sleeping Pill ANDA
• AstraZeneca Links Up With Targacept In $1.2B Deal
• Direct Purchasers Propose Counsel In AndroGel MDL
• Q&A With Finnegan's J. Michael Jakes
• Fed. Circ. Nixes $15M Infringement Ruling V. Arthrex
• Boston Scientific Settles ERISA Suit For $8M
• PBM Wins $13.5M In Baby Formula Advertising Suit
• Court Says Suit Over Stryker Hip Implant Preempted
• Judge Won't Compel Boston Scientific Privileged Docs
• Investor Sues Hemispherx As FDA Denies Fatigue Drug
• Panel Nixes Pfizer Fraudulent Marketing MDL
• Judge Rips Fosamax MDL Lawyers' Spat Over Clients
• Zimmer Securities Fraud Class Action Gets The Boot
• 6th Circ. Affirms Dismissals From Novartis MDL
• Shire, Teva Settle Contract Spat Over Adderall Supplies
• Suits Over Novartis Eczema Drug Return To NJ Court
• Bayer Buys Cancer-Fighting Antibody Rights For $426M
• Sidley Austin Starts Up Silicon Valley Office
• Judge Guts State's 'Slash And Burn' Zyprexa Suit
• Duane Morris Snags Fish & Richardson IP Principal
• 21 States Win $25M Settlement In Vitamin Suit
• Stryker Buys Medical Device Firm Ascent For $525M
• European Vioxx Claims Don't Stand In US: 5th Circ.
• Drugmakers Fined $6M Over Viagra, Cialis, Levitra